

PATENT APPLICATION #3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Atty. Dkt.: Q67547

Masashi NAKATSUKA, et al.

Appln. No.

Group Art Unit: Unknown

Confirmation No.: Unknown

Examiner: Unknown

Filed: January 14, 2002

For: HETEROAROMATIC RING COMPOUNDS

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. U.S. Patent No. 6,100,260, issued August 8, 2000 to Nakatsuka et al. This reference is identified on the International Search Report.
2. European Patent Application No. 0 248 399 A1, issued December 9, 1987 to Ozato et al. ~~This reference is identified on the International Search Report.~~
3. U.S. Patent No. 5,102,897, issued April 7, 1992 to Boschelli et al.
4. European Patent Application No. 0 371 438 A2, published June 6, 1990.
5. WO 99/23091, published May 14, 1999.
6. WO 00/47578, published August 17, 2000.
7. Japanese Unexamined Patent Publication No. 7-149745, published June 13, 1995, with English Abstract.
8. Japanese Unexamined Patent Publication No. 8-41008, published February 13, 1996, with English Abstract.

NAKATSUKA et al.  
Q67547  
Information Disclosure Statement


9. Japanese Unexamined Patent Publication No. 9-59258, published March 4, 1997, with English Abstract.

One copy of each of the listed documents is submitted herewith, along with a copy of the International Search Report which identifies References 1 and 2 above.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date for an application other than a continued prosecution application (CPA) under §1.53(d); (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,



SUGHRUE MION, PLLC  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037-3213  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

J. Frank Osha  
Registration No. 24,625

Date: January 14, 2002

Substitute for form 1449 A & B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	Unknown
				Confirmation Number	Unknown
				Filing Date	January 14, 2002
				First Named Inventor	Masashi NAKATSUKA
				Art Unit	Unknown
Examiner Name	Unknown				
Attorney Docket Number	Q67547				
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US 6,100,260		08-08-2000	Nakatsuka et al.
		US 5,102,897		04-07-1992	Boschelli et al.
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
		EP	0 248 399	A1	12-09-1987	Sumitomo Pharmaceuticals Co., Ltd.	
		EP	0 371 438	A2	06-06-1990	Warner-Lambert Co.	
		WO	99/23091	A1	05-14-1999	Boehringer Ingelheim Pharmaceuticals, Inc.	
		WO	00/47578	A1	08-17-2000	3-Dimensional Pharmaceuticals, Inc.	
		JP	7-149745	A	06-13-1995	Hisamitsu Pharmaceutical Co., Ltd.	Abstract
		JP	8-41008	A	02-13-1996	Ono Pharmaceutical Co., Ltd.	Abstract
		JP	9-59258	A	03-04-1997	Ono Pharmaceutical Co., Ltd.	Abstract

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.